We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, Industry Agree on Draft Commitments for BsUFA III
FDA, Industry Agree on Draft Commitments for BsUFA III
The FDA has reached an agreement on draft commitments to the biosimilars industry for the upcoming iteration of the biosimilar user fee program, BsUFA III, which will cover fiscal 2023 through 2027.